BioRestorative Therapies (BRTX) Net Cash Flow (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Net Cash Flow came in at $923917.0 in Q4 2025, up 198.13% YoY from $309907.4 in Q4 2024, and up 197.08% on a QoQ basis from -$951670.0 in Q3 2025.
BioRestorative Therapies (BRTX) Net Cash Flow (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Net Cash Flow data on file, last reported at $923917.0 in Q4 2025.
- Quarterly Net Cash Flow rose 198.13% year-over-year to $923917.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $952261.0 (up 383.0% YoY) and the FY2025 annual result came in at $952261.0, up 383.0% from the prior year.
- Net Cash Flow climbed to $923917.0 in Q4 2025, from -$951670.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $19.9 million in Q4 2021 to a low of -$11.4 million in Q3 2022.
- A 5-year average of -$97275.1 and a median of -$596532.5 in 2021 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 589.87% in 2021, down 18190.53% in 2021.
- Tracing BRTX's Net Cash Flow over 5 years: stood at $19.9 million in 2021, then plunged by 124.38% to -$4.9 million in 2022, then soared by 67.29% to -$1.6 million in 2023, then jumped by 40.77% to -$941554.0 in 2024, then jumped by 198.13% to $923917.0 in 2025.
- The last three Net Cash Flow figures came in at $923917.0 (Q4 2025), -$951670.0 (Q3 2025), and $299115.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 923,917.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 923,917.00 |
| Dec 31, 2025 | 923,917.00 |
| Sep 30, 2025 | -951,670.00 |
| Sep 30, 2025 | -951,670.00 |
| Jun 30, 2025 | 299,115.00 |
| Jun 30, 2025 | 299,115.00 |
| Mar 31, 2025 | 680,899.00 |
| Mar 31, 2025 | 680,899.00 |
| Dec 31, 2024 | -941,554.00 |
| Dec 31, 2024 | -941,554.00 |
| Sep 30, 2024 | -762,803.00 |
| Sep 30, 2024 | -762,803.00 |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 272,703.00 |
| Mar 31, 2024 | 272,703.00 |
| Dec 31, 2023 | -1.59 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | 653,223.00 |
| Sep 30, 2023 | 653,223.00 |